ES2058592T3 - El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales. - Google Patents

El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.

Info

Publication number
ES2058592T3
ES2058592T3 ES89810464T ES89810464T ES2058592T3 ES 2058592 T3 ES2058592 T3 ES 2058592T3 ES 89810464 T ES89810464 T ES 89810464T ES 89810464 T ES89810464 T ES 89810464T ES 2058592 T3 ES2058592 T3 ES 2058592T3
Authority
ES
Spain
Prior art keywords
manufacture
neuronal diseases
physiologically active
active substances
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89810464T
Other languages
English (en)
Inventor
Jin-Emon C O Inst Of B Konishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2058592T3 publication Critical patent/ES2058592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A SUSTANCIAS FISIOLOGICAMENTE ACTIVAS EXTRAIDAS DE TEJIDOS INFECTADOS QUE TIENEN UN EFECTO ESTIMULANTE DEL CRECIMIENTO DE NERVIOS ANALOGO AL DEL FACTOR DE CRECIMIENTO DE NERVIOS (NGF), PARA EL TRATAMIENTO DE ENFERMEDADES CEREBRALES Y NEURONALES. ESTAS SUSTANCIAS SON UTILES COMO FARMACOS PARA EL TRATAMIENTO DE DIVERSAS ENFERMEDADES CEREBRALES Y NEURONALES TALES COMO LA DEMENCIA, NEUROLOGIA POST - HERPETICA, EDEMA CEREBRAL Y DEGENERACION ESPINO - CEREBRAL.
ES89810464T 1988-06-20 1989-06-16 El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales. Expired - Lifetime ES2058592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63152492A JP2539665B2 (ja) 1988-06-20 1988-06-20 神経疾患治療剤

Publications (1)

Publication Number Publication Date
ES2058592T3 true ES2058592T3 (es) 1994-11-01

Family

ID=15541651

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89810464T Expired - Lifetime ES2058592T3 (es) 1988-06-20 1989-06-16 El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.

Country Status (6)

Country Link
US (1) US5013558A (es)
EP (1) EP0348353B1 (es)
JP (1) JP2539665B2 (es)
AT (1) ATE94069T1 (es)
DE (1) DE68908971T2 (es)
ES (1) ES2058592T3 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588109B2 (ja) * 1993-03-19 1997-03-05 日本臓器製薬株式会社 鎮痛剤
JP3213831B2 (ja) * 1993-08-06 2001-10-02 日本臓器製薬株式会社 被検物質の活性測定方法
JP3213832B2 (ja) * 1993-08-06 2001-10-02 日本臓器製薬株式会社 被検物質の活性測定法
JP2594222B2 (ja) * 1993-09-28 1997-03-26 日本臓器製薬株式会社 新規生理活性物質−ｋｆ
JP2732379B2 (ja) * 1995-12-18 1998-03-30 日本臓器製薬株式会社 知覚異常改善剤
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
JP4033936B2 (ja) * 1997-01-08 2008-01-16 日本臓器製薬株式会社 一酸化窒素産生抑制剤
JPH1180005A (ja) * 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
KR19990044835A (ko) 1997-11-28 1999-06-25 고니시 진우에몬 생약추출물
CA2270050A1 (en) * 1998-04-27 1999-10-27 Jin-Emon Konishi A therapeutic agent for ischemic diseases
EP1046397A3 (en) 1999-04-15 2003-04-23 Nippon Zoki Pharmaceutical Co. Ltd. Novel bioactivating substance
KR20010082721A (ko) 2000-02-18 2001-08-30 고니시 진우에몬 지방산 함유 조성물
JP2002068973A (ja) * 2000-06-16 2002-03-08 Meiji Milk Prod Co Ltd 幹細胞分化誘導促進剤
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
KR101097138B1 (ko) 2002-10-31 2011-12-22 니폰 조키 세야쿠 가부시키가이샤 섬유근통증 치료제
BR0316560A (pt) * 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
AU2005243247B2 (en) * 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1773857A4 (en) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
US20060134646A1 (en) 2004-12-17 2006-06-22 Ansari Aftab A Method for treatment of HIV infection
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
TWI406664B (zh) 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑
WO2009028605A1 (ja) 2007-08-31 2009-03-05 Kyushu University, National University Corporation 抗がん剤による末梢神経障害の予防又は軽減剤
NZ588583A (en) * 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
CN101732348B (zh) * 2008-11-11 2015-01-14 威世药业（如皋）有限公司 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
TWI483729B (zh) 2010-03-11 2015-05-11 Nippon Zoki Pharmaceutical Co 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑
TWI504894B (zh) 2010-06-25 2015-10-21 Nippon Zoki Pharmaceutical Co 被檢物質的判定或評價方法
CN103476923B (zh) 2010-10-14 2015-04-29 日本脏器制药株式会社 软骨细胞中的胶原蛋白和蛋白聚糖合成的促进方法
CN115629217A (zh) 2013-04-30 2023-01-20 日本脏器制药株式会社 提取物和含有该提取物的制剂
US11129976B2 (en) 2016-02-24 2021-09-28 Osaka University Test method
WO2018056412A1 (ja) 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
EP3592369A4 (en) * 2017-03-06 2020-09-09 Jun Liu MEANS OF INHIBITING OR MITIGATING BETA-INDUCED DAMAGE
US20220096561A1 (en) * 2019-01-30 2022-03-31 Jun Liu Inhibiting or alleviating agent for inflammation in the brain
US20250213622A1 (en) * 2022-04-01 2025-07-03 Star Bright Bio-Tech Limited Use of extract from rabbit skin inflamed by vaccinia virus in treating parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53101515A (en) * 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS59118711A (ja) * 1982-12-25 1984-07-09 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質
JP2539674B2 (ja) * 1987-11-06 1996-10-02 日本臓器製薬株式会社 新規生理活性物質

Also Published As

Publication number Publication date
JPH01319422A (ja) 1989-12-25
EP0348353A2 (en) 1989-12-27
EP0348353A3 (en) 1990-10-31
DE68908971D1 (de) 1993-10-14
JP2539665B2 (ja) 1996-10-02
EP0348353B1 (en) 1993-09-08
US5013558A (en) 1991-05-07
DE68908971T2 (de) 1994-01-13
ATE94069T1 (de) 1993-09-15

Similar Documents

Publication Publication Date Title
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
RU93058654A (ru) Способ определения полезности пролекарств, превращающихся печенью, их применение в терапии, пролекарство
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
ES551441A0 (es) Procedimiento para el tratamiento de formas de dosificacion farmaceuticas
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
EP1295604A4 (en) PREVENTIVA AND THERAPEUTIA FOR DEMYELINISATION-ASSOCIATED DISEASES
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE69602412D1 (de) Ophthalmische Zubereitung zur Behandlung oder Prävention von trockenem Auge und Krankheiten, die dadurch verursacht werden, enthaltend 12-Sulfodehydroabietsäure
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ATE133859T1 (de) Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen
DE60018554D1 (de) Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
DK0559145T3 (da) Lægemiddel til truende abort
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DK0435153T3 (da) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, fremgangsmåde til dens fremstilling og lægemidler med indhold deraf
ES2095984T3 (es) 2,3-dihidropirano(2,3-b)piridinas aminometil sustituidas, procedimiento para su preparacion y su uso en medicamentos.
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 348353

Country of ref document: ES